Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2053504rdf:typepubmed:Citationlld:pubmed
pubmed-article:2053504lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:2053504lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2053504lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:2053504lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2053504lifeskim:mentionsumls-concept:C0282215lld:lifeskim
pubmed-article:2053504lifeskim:mentionsumls-concept:C0205173lld:lifeskim
pubmed-article:2053504lifeskim:mentionsumls-concept:C1880496lld:lifeskim
pubmed-article:2053504pubmed:issue2lld:pubmed
pubmed-article:2053504pubmed:dateCreated1991-7-24lld:pubmed
pubmed-article:2053504pubmed:abstractTextAztreonam, the first monocyclic beta-lactam antibiotic with pure anti-Gram-negative activity, combined with flucloxacillin, a penicillinase resistant penicillin, was given as empirical treatment of 53 serious infections in very elderly people. Eighteen of the cases had positive blood cultures and 11 had a clinical picture of sepsis without positive blood cultures: Of 49 evaluable infections, 45 (92%) were cured. In 40% of the infections, antibiotic treatment could be narrowed after 72 hours to one antibiotic. Diarrhoea, mostly transitory, was the only side-effect. Aztreonam-flucloxacillin combination is a safe and effective empirical treatment regimen for serious infections in very elderly patients.lld:pubmed
pubmed-article:2053504pubmed:languageenglld:pubmed
pubmed-article:2053504pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2053504pubmed:citationSubsetIMlld:pubmed
pubmed-article:2053504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2053504pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2053504pubmed:statusMEDLINElld:pubmed
pubmed-article:2053504pubmed:monthMarlld:pubmed
pubmed-article:2053504pubmed:issn0002-0729lld:pubmed
pubmed-article:2053504pubmed:authorpubmed-author:NestorLLlld:pubmed
pubmed-article:2053504pubmed:authorpubmed-author:VerbistLLlld:pubmed
pubmed-article:2053504pubmed:authorpubmed-author:PelemansWWlld:pubmed
pubmed-article:2053504pubmed:authorpubmed-author:KnockaertD...lld:pubmed
pubmed-article:2053504pubmed:authorpubmed-author:DejaegerEElld:pubmed
pubmed-article:2053504pubmed:issnTypePrintlld:pubmed
pubmed-article:2053504pubmed:volume20lld:pubmed
pubmed-article:2053504pubmed:ownerNLMlld:pubmed
pubmed-article:2053504pubmed:authorsCompleteYlld:pubmed
pubmed-article:2053504pubmed:pagination135-9lld:pubmed
pubmed-article:2053504pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:meshHeadingpubmed-meshheading:2053504-...lld:pubmed
pubmed-article:2053504pubmed:year1991lld:pubmed
pubmed-article:2053504pubmed:articleTitleAztreonam-flucloxacillin double beta-lactam treatment as empirical therapy of serious infections in very elderly patients.lld:pubmed
pubmed-article:2053504pubmed:affiliationDepartment of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium.lld:pubmed
pubmed-article:2053504pubmed:publicationTypeJournal Articlelld:pubmed